Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on August 28, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Merger with Vertex approved: 79,240,098 votes for versus 13,618 against, satisfying the final outstanding closing condition.
Crinetics Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Merger with Vertex approved: 79,240,098 votes for versus 13,618 against, satisfying the final outstanding closing condition
- 74.71% shareholder participation, with 79,264,631 of 106,095,205 shares represented
- Closing anticipated around September 1, 2026, subject to remaining transaction conditions
- Executive merger-related compensation rejected 44,803,403 to 33,854,149, but advisory vote does not affect closing
- Crinetics shareholders face transition to a wholly owned Vertex subsidiary upon merger completion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Crinetics Pharmaceuticals, Inc. 8-K filings
Get the next CRNX 8-K as it lands
Follow CRNX for push alerts, or ask the research agent what this filing means.